Krüppel‐like factor 4 promotes c‐Met amplification‐mediated gefitinib resistance in non‐small‐cell lung cancer

Gefitinib has been widely used in the first‐line treatment of advanced EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9‐14 months of treatment. This study revealed that Krüppel‐like factor 4 (KLF4) contributes to the formation...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Sci
Main Authors: Feng, Wei, Xie, Qianyi, Liu, Suo, Ji, Ying, Li, Chunyun, Wang, Chunle, Jin, Longyu
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989843/
https://ncbi.nlm.nih.gov/pubmed/29624806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13601
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items